Meloxicam/rizatriptan, sold under the brand name Symbravo, is a fixed-dose combination medication used for the treatment of migraine. It is a combination of meloxicam, a nonsteroidal anti-inflammatory medication; and rizatriptan (as rizatriptan benzoate), a serotonin (5-HT) 1B/1D receptor agonist (triptan). It is taken by mouth. Meloxicam/rizatriptan was approved for medical use in the United States in January 2025.
Medical uses Meloxicam/rizatriptan is indicated for the acute treatment of migraine with or without aura in adults.
Society and culture
Legal status Meloxicam/rizatriptan was approved for medical use in the United States in January 2025.
References
External links Clinical trial number NCT03896009 for "Maximizing Outcomes in Treating Acute Migraine (MOMENTUM)" at ClinicalTrials.gov Clinical trial number NCT04163185 for "Initiating Early Control of Migraine Pain and Associated Symptoms (INTERCEPT)" at ClinicalTrials.gov
